|
Federal
Register Notices > Notice
of Application >
American Radiolabeled Chemical, Inc
FR Doc E7-14267 [Federal Register: July 24, 2007 (Volume 72, Number 141)] [
Notices] [Page 40331] From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr24jy07-115]
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled Substances; Notice of Application
Pursuant to Sec. 1301.33(a)
of Title 21 of the Code of Federal Regulations (CFR),
this is notice that on May 23, 2007, American Radiolabeled Chemical, Inc., 101
Arc Drive, St. Louis, Missouri 63146, made application by renewal to the Drug
Enforcement Administration (DEA) to be registered as a bulk manufacturer of the
basic classes of controlled substances listed in schedule I and II:
|
Drug
|
Schedule
|
|
Gamma hydroxybutyric acid (2010)
|
I
|
|
Ibogaine (7260)
|
I
|
|
Lysergic acid diethylamide (7315)
|
I
|
|
Tetrahydrocannabinols (7370)
|
I
|
|
Dimethyltryptamine (7435)
|
I
|
|
1-[1-(2-Thienyl) cyclohexyl]piperidine(7470) |
I
|
|
Dihydromorphine (9145)
|
I
|
|
Normorphine (9313)
|
I
|
|
Amphetamine (1100)
|
II
|
|
Methamphetamine (1105)
|
II
|
|
Amobarbital (2125)
|
II
|
|
Phencyclidine (7471)
|
II
|
|
Phenylacetone (8501)
|
II
|
|
Cocaine (9041)
|
II
|
|
Codeine (9050)
|
II
|
|
Dihydrocodeine (9120)
|
II
|
|
Oxycodone (9143)
|
II
|
|
Hydromorphone (9150)
|
II
|
|
Ecgonine (9180)
|
II
|
|
Hydrocodone (9193)
|
II
|
|
Meperidine (9230)
|
II
|
|
Metazocine (9240)
|
II
|
|
Dextropropoxyphene, bulk (non-dosage forms)(9273)
|
II
|
|
Morphine (9300)
|
II
|
|
Thebaine (9333)
|
II
|
|
Oxymorphone (9652)
|
II
|
|
Phenazocine (9715)
|
II
|
|
Fentanyl (9801)
|
II
|
The company plans to manufacture small quantities of the listed controlled
substances as radiolabeled compounds for biochemical research.
Any other such applicant and any person who is presently registered with DEA
to manufacture such a substance may file comments or objections to the issuance
of the proposed registration pursuant to 21 CFR 1301.33(a).
Any such written comments or objections being sent via regular mail should be
addressed, in quintuplicate, to the Drug Enforcement Administration, Office of
Diversion Control, Federal Register Representative (ODL), Washington, DC 20537,
or any being sent via express mail should be sent to Drug Enforcement
Administration, Office of Diversion Control, Federal Register Representative (ODL),
2401 Jefferson Davis Highway, Alexandria, Virginia 22301; and must be filed no
later than September 24, 2007.
Dated: July 10, 2007.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion
Control, Drug Enforcement Administration.
[FR Doc. E7-14267 Filed 7-23-07; 8:45 am]
BILLING CODE 4410-09-P
NOTICE: This is an
unofficial version. An official version of these publications may be obtained
directly from the Government Printing Office (GPO).
|